|
US6696065B1
(en)
|
1995-05-04 |
2004-02-24 |
Aventis Pastuer Limited |
Acellular pertussis vaccines and methods of preparation thereof
|
|
TR199701547T1
(xx)
*
|
1995-06-07 |
1998-03-21 |
Smithkline Beecham Biologicals S.A. |
Polisakarit antijen protein e�leni�i i�eren a��.
|
|
DE69736709T2
(de)
*
|
1996-07-02 |
2007-10-04 |
Sanofi Pasteur Ltd., Toronto |
Vielwertige dtp-polio-impfstoffe
|
|
US6248334B1
(en)
*
|
1997-01-08 |
2001-06-19 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
|
|
AU763349B2
(en)
*
|
1998-02-05 |
2003-07-17 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
|
|
US7018637B2
(en)
*
|
1998-02-23 |
2006-03-28 |
Aventis Pasteur, Inc |
Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
|
|
ATE459373T1
(de)
|
1999-03-19 |
2010-03-15 |
Glaxosmithkline Biolog Sa |
Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
|
|
FR2806304B1
(fr)
*
|
2000-03-17 |
2002-05-10 |
Aventis Pasteur |
Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
|
|
SI21352A
(sl)
|
2001-01-23 |
2004-06-30 |
Aventis Pasteur |
Multivalentno meningokokno cepivo iz konjugata polisaharida-proteina
|
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
|
HUE031886T2
(en)
|
2002-10-11 |
2017-08-28 |
Glaxosmithkline Biologicals Sa |
Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
|
|
CA2503946C
(en)
|
2002-11-01 |
2016-08-16 |
Glaxosmithkline Biologicals S.A. |
Drying process
|
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
|
EP2172213B1
(en)
|
2003-01-30 |
2013-04-03 |
Novartis AG |
Injectable vaccines against multiple meningococcal serogroups
|
|
EP2210607B1
(en)
|
2003-09-26 |
2011-08-17 |
Exelixis Inc. |
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
|
|
NZ546430A
(en)
|
2003-10-02 |
2009-04-30 |
Novartis Vaccines & Diagnostic |
Liquid vaccines for multiple meningococcal serogroups
|
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
|
GB0406013D0
(en)
|
2004-03-17 |
2004-04-21 |
Chiron Srl |
Analysis of saccharide vaccines without interference
|
|
NZ550533A
(en)
|
2004-04-30 |
2010-02-26 |
Novartis Vaccines & Diagnostic |
Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
|
|
GB0409745D0
(en)
*
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
|
GB0411387D0
(en)
|
2004-05-21 |
2004-06-23 |
Chiron Srl |
Analysis of saccharide length
|
|
GB0413868D0
(en)
|
2004-06-21 |
2004-07-21 |
Chiron Srl |
Dimensional anlaysis of saccharide conjugates
|
|
GB0428394D0
(en)
*
|
2004-12-24 |
2005-02-02 |
Chiron Srl |
Saccharide conjugate vaccines
|
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
|
GB0502096D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Purification of streptococcal capsular polysaccharide
|
|
GB0505518D0
(en)
|
2005-03-17 |
2005-04-27 |
Chiron Srl |
Combination vaccines with whole cell pertussis antigen
|
|
CA2605179A1
(en)
|
2005-04-18 |
2006-10-26 |
Novartis Vaccines And Diagnostics, Inc. |
Expressing hepatitis b virus surface antigen for vaccine preparation
|
|
PE20110072A1
(es)
|
2005-06-27 |
2011-02-04 |
Glaxosmithkline Biolog Sa |
Composicion inmunogenica
|
|
JP5135220B2
(ja)
|
2005-09-01 |
2013-02-06 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー |
血清群ｃ髄膜炎菌を含む複数ワクチン接種
|
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
|
US10828361B2
(en)
|
2006-03-22 |
2020-11-10 |
Glaxosmithkline Biologicals Sa |
Regimens for immunisation with meningococcal conjugates
|
|
PL2004225T3
(pl)
|
2006-03-22 |
2012-09-28 |
Novartis Ag |
Schematy immunizacji koniugatami meningokokowymi
|
|
JP5814507B2
(ja)
|
2006-09-07 |
2015-11-17 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ワクチン
|
|
GB0700136D0
(en)
|
2007-01-04 |
2007-02-14 |
Glaxosmithkline Biolog Sa |
Process for manufacturing vaccines
|
|
CA2777837C
(en)
|
2008-10-27 |
2017-07-11 |
Novartis Ag |
Purification method
|
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
|
GB0822633D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Formulation
|
|
BR112012009014B8
(pt)
|
2009-09-30 |
2022-10-04 |
Novartis Ag |
Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
|
|
HUE034251T2
(en)
|
2009-10-30 |
2018-02-28 |
Glaxosmithkline Biologicals Sa |
Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
|
|
WO2011080595A2
(en)
|
2009-12-30 |
2011-07-07 |
Novartis Ag |
Polysaccharide immunogens conjugated to e. coli carrier proteins
|
|
AU2011288203A1
(en)
|
2010-03-18 |
2012-08-23 |
Novartis Ag |
Adjuvanted vaccines for serogroup B meningococcus
|
|
EP2612148B1
(en)
|
2010-09-04 |
2019-06-12 |
GlaxoSmithKline Biologicals SA |
Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
|
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
|
CA2860331A1
(en)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Compounds
|
|
WO2012117377A1
(en)
|
2011-03-02 |
2012-09-07 |
Novartis Ag |
Combination vaccines with lower doses of antigen and/or adjuvant
|
|
GB201106340D0
(en)
*
|
2011-04-14 |
2011-06-01 |
Isis Innovation |
Composition
|
|
US9358284B2
(en)
|
2011-09-14 |
2016-06-07 |
Glaxosmithkline Biologicals Sa |
Methods for making saccharide-protein glycoconjugates
|
|
RU2636350C2
(ru)
|
2011-11-07 |
2017-11-22 |
Новартис Аг |
МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
|
|
GB2495341B
(en)
|
2011-11-11 |
2013-09-18 |
Novartis Ag |
Fermentation methods and their products
|
|
DE102011122891B4
(de)
|
2011-11-11 |
2014-12-24 |
Novartis Ag |
Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
|
|
DE102011118371B4
(de)
|
2011-11-11 |
2014-02-13 |
Novartis Ag |
Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
|
|
EP2592137A1
(en)
|
2011-11-11 |
2013-05-15 |
Novartis AG |
Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
|
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
|
EP2822584A1
(en)
|
2012-03-08 |
2015-01-14 |
Novartis AG |
Combination vaccines with tlr4 agonists
|
|
RU2014151567A
(ru)
|
2012-05-22 |
2016-07-10 |
Новартис Аг |
Конъюгат менингококка серогруппы х
|
|
JP6324961B2
(ja)
|
2012-09-06 |
2018-05-16 |
ノバルティス アーゲー |
血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
|
|
RU2015106791A
(ru)
|
2012-10-03 |
2016-11-20 |
Глэксосмитиклайн Байолоджикалз Са |
Иммуногенные композиции
|
|
EP2906239A1
(en)
|
2012-10-12 |
2015-08-19 |
GlaxoSmithKline Biologicals SA |
Non-cross-linked acellular pertussis antigens for use in combination vaccines
|
|
US20150320852A1
(en)
|
2012-12-18 |
2015-11-12 |
Glaxosmithkline Biologicals Sa |
Conjugates for protecting against diphtheria and/or tetanus
|
|
CN111499679B
(zh)
|
2013-01-04 |
2021-07-06 |
台湾浩鼎生技股份有限公司 |
具有较高碳水化合物抗原密度的疫苗及新颖皂素佐剂
|
|
CN104174019A
(zh)
*
|
2014-09-23 |
2014-12-03 |
成都康华生物制品有限公司 |
四价脑膜炎球菌多糖载体蛋白结合疫苗
|
|
US9107906B1
(en)
|
2014-10-28 |
2015-08-18 |
Adma Biologics, Inc. |
Compositions and methods for the treatment of immunodeficiency
|
|
EP3034516A1
(en)
|
2014-12-19 |
2016-06-22 |
Novartis AG |
Purification of streptococcal capsular polysaccharide
|
|
BE1024634B1
(fr)
|
2016-04-05 |
2018-05-14 |
Gsk Vaccines S.R.L. |
Compositions immunogenes
|
|
US11027005B2
(en)
|
2016-10-20 |
2021-06-08 |
Km Biologics Co., Ltd. |
Method for producing Hib conjugate vaccine using PRP with lowered molecular weight
|
|
US10259865B2
(en)
|
2017-03-15 |
2019-04-16 |
Adma Biologics, Inc. |
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
|
|
EP3799884A1
(en)
|
2019-10-01 |
2021-04-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
|
US11173199B2
(en)
*
|
2019-11-13 |
2021-11-16 |
Alopexx Inc. |
Low contaminant compositions
|
|
WO2021174330A1
(en)
*
|
2020-03-05 |
2021-09-10 |
Nuecology Biomedical Inc. |
Amphiphilic alginate-oleic acid macromolecules and process for preparation therof
|
|
MX2023005517A
(es)
|
2020-11-13 |
2023-08-21 |
Glaxosmithkline Biologicals Sa |
Novedosos portadores y métodos de conjugación.
|